Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
NOVARTIS PHARMACEUTICALS CORPORATION v. JANSSEN PHARMACEUTICALS COMPANY OF JOHNSON & JOHNSON
Case Number:
1:19-cv-00576
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 25, 2019
Novartis Settles Suit Saying Janssen Maligned Rival Drug
Novartis agreed Thursday to settle its D.C. federal lawsuit that accused Janssen of touting skewed study results to make it seem like Janssen's plaque psoriasis treatment, Tremfya, is less dangerous and more effective than Novartis' own Cosentyx.
-
March 06, 2019
CORRECTED: Novartis Wants Janssen Barred From Disparaging Rival Drug
Novartis Pharmaceuticals Corp. has asked a D.C. federal court to force Janssen Pharmaceuticals Inc. to stop touting skewed study results that make it seem like Janssen’s plaque psoriasis treatment, Tremfya, is less dangerous and more effective than Novartis’ own Cosentyx. (Correction: A previous version of this article misstated Novartis' allegations. The error has been corrected.)
-
March 01, 2019
Novartis Slaps J&J Unit With Psoriasis Drug False Ad Suit
Novartis Pharmaceuticals Corp. hit a Johnson & Johnson subsidiary with a false advertising suit in D.C. federal court Friday, saying the company is wrongly claiming its drug to treat plaque psoriasis, Tremfya, is better than the Novartis version, Cosentyx, at conferences.